<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04776187</url>
  </required_header>
  <id_info>
    <org_study_id>Gadolinium 1.0</org_study_id>
    <nct_id>NCT04776187</nct_id>
  </id_info>
  <brief_title>Safety Evaluation of Linear and Macrocyclic Gadolinium Based Contrast Agents for Patients With Mild to Moderate Renal Insufficiency Undergoing Enhanced Magnetic Resonance Imaging</brief_title>
  <official_title>Safety Evaluation of Linear and Macrocyclic Gadolinium-Based Contrast Agents for Patients With Mild to Moderate Renal Insufficiency Undergoing Enhanced Magnetic Resonance Imaging (Interventional Prospective Study) Clinical Trial Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Central Hospital of Lishui City</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu Hengrui Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Central Hospital of Lishui City</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety of linear and macrocyclic&#xD;
      gadolinium-based contrast agents for patients with mild to moderate renal insufficiency. The&#xD;
      study will compare the incidence of adverse events of gadodiamide and gadoteric Acid&#xD;
      Meglumine Salt for patients with mild to moderate renal insufficiency undergoing enhanced&#xD;
      magnetic resonance imaging.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      According to the requirements of the study, 600 cases of patients with mild to moderate renal&#xD;
      insufficiency were enrolled. Gadodiamide and Gadoteric acid meglumine salt were used for&#xD;
      enhanced MRI. Observe the adverse reactions within 60 minutes of using the gadolinium&#xD;
      contrast agents; follow up by telephone at 3, 6, 12, and 24 months after the inspection. The&#xD;
      primary endpoint is the incidence of the various adverse events, and the secondary endpoints&#xD;
      are changes of serum creatinine and inflammatory factors (TNF-α, hs-CRP, IL-6) before and&#xD;
      after CE-MRI, patient skin examination and evaluation (evaluation of relevant indicators of&#xD;
      skin biopsy).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of various adverse events</measure>
    <time_frame>From the date of contrast injection to the incidence of adverse events, assessd up to 60 minutes</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The incidence of various adverse events</measure>
    <time_frame>From the date of contrast injection to the incidence of adverse events, assessd up to 3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The incidence of various adverse events</measure>
    <time_frame>From the date of contrast injection to the incidence of adverse events, assessd up to 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The incidence of various adverse events</measure>
    <time_frame>From the date of contrast injection to the incidence of adverse events, assessd up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The incidence of various adverse events</measure>
    <time_frame>From the date of contrast injection to the incidence of adverse events, assessd up to 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes of serum creatinine before and after CE-MRI at 3 days</measure>
    <time_frame>From the date of contrast injection to the changes of serum creatinine before and after CE-MRI, assessed up to 3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of TNF-α before and after CE-MRI at 3 days</measure>
    <time_frame>From the date of contrast injection to the changes of TNF-α before and after CE-MRI, assessed up to 3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of hs-CRP before and after CE-MRI at 3 days</measure>
    <time_frame>From the date of contrast injection to the changes of hs-CRP before and after CE-MRI, assessed up to 3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of IL-6 before and after CE-MRI at 3 days</measure>
    <time_frame>From the date of contrast injection to the changes of IL-6 before and after CE-MRI, assessed up to 3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of relevant indicators of skin biopsy</measure>
    <time_frame>From the date of contrast injection to the clinical manifestations appear, assessed up to 24 months</time_frame>
    <description>proliferation of fibroblasts in subcutaneous tissue, thickening of collagen fiber bundles</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Nephrogenic Fibrosing Dermopathy</condition>
  <arm_group>
    <arm_group_label>Gadodiamide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who have undergone contrast-enhanced MRI using Gadodiamide contrast agent for clinical purposes.&#xD;
Generic name: Gadodiamide Injection; Product name: OMNISCAN; Sample specifications: 15ml: 4.305g (a sterile solution containing 287mg/ml gadodiamide).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gadoteric Acid Meglumine Salt</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who have undergone contrast-enhanced MRI using Gadoteric Acid Meglumine Salt contrast agent for clinical purposes.&#xD;
Generic name: Gadoteric Acid Meglumine Salt Injection; Commodity name: Jia Di Xian; Sample specifications: 15ml: 5.654g (a sterile solution containing 377mg/ml gadoteric acid meglumine salt).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gadodiamide</intervention_name>
    <description>Gadodiamide Injection(OMNISCAN™)</description>
    <arm_group_label>Gadodiamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gadoteric Acid Meglumine Salt</intervention_name>
    <description>Gadoteric Acid Meglumine Salt Injection(Jia Di Xian™)</description>
    <arm_group_label>Gadoteric Acid Meglumine Salt</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients aged 18 to 80 years old who require gadolinium-based CE-MRI;&#xD;
&#xD;
          2. Patients with renal function 30ml/min/1.73m2≤eGFR&lt;90/min/1.73m2;&#xD;
&#xD;
          3. Patients who are able and willing to comply with the required inspection requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient who experienced allergic reactions to previous gadolinium-based contrast&#xD;
             agents;&#xD;
&#xD;
          2. Patient who had used gadolinium-based contrast agents within 3 months;&#xD;
&#xD;
          3. Patient with acute renal failure;&#xD;
&#xD;
          4. Patient who cannot comply with or cannot tolerate the necessary fluid replenishment&#xD;
             procedures;&#xD;
&#xD;
          5. Patient with major mental illness, impaired consciousness, or other diseases&#xD;
             considered by researchers to affect observation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jiansong S Ji, MD,PhD</last_name>
    <phone>2285018</phone>
    <phone_ext>0578</phone_ext>
    <email>lschrjjs@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lishui Central Hospital</name>
      <address>
        <city>Lishui</city>
        <state>Zhejiang</state>
        <zip>323000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiansong S Ji, MD,PhD</last_name>
      <phone>2285018</phone>
      <phone_ext>0578</phone_ext>
      <email>lschrjjs@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 11, 2021</study_first_submitted>
  <study_first_submitted_qc>February 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2021</study_first_posted>
  <last_update_submitted>February 26, 2021</last_update_submitted>
  <last_update_submitted_qc>February 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Humans</keyword>
  <keyword>gadodiamide</keyword>
  <keyword>MRI</keyword>
  <keyword>Renal Insufficiency</keyword>
  <keyword>Drug-Related Adverse Reactions</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Nephrogenic Fibrosing Dermopathy</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 1, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT04776187/ICF_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 1, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT04776187/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

